Gender differences in associations of cognitive impairments with homocysteine in schizophrenia

S Zhou, Y Huang, Q Kuang, S Yan, Y Feng, H Li… - Asian Journal of …, 2022 - Elsevier
Results There were significant differences between schizophrenia patients and healthy
controls in age (P< 0.001), BMI (P< 0.001), and education (P< 0.001). Thus, we controlled for …

COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy

M Bondrescu, L Dehelean, SS Farcas, I Papava… - Biomolecules, 2024 - mdpi.com
Pharmacogenetic markers are current targets for the personalized treatment of psychosis.
Limited data exist on COMT and NRG1 polymorphisms in relation to risperidone treatment …

COGNITIVE IMPAIRMENT IN MOOD DISORDERS: NEUROPSYCHOLOGY, MULTIMODAL BRAIN IMAGING, AND THE EFFECT OF NEUROINFLAMMATION

F Calesella - 2024 - iris.unisr.it
Il peso dei disturbi dell'umore continua a crescere, con circa un terzo dei pazienti che non
risponde agli antidepressivi. Una diagnosi accurata e tempestiva è essenziale per la …